# US 2025/0144038 A1 · Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144038 A1
- Document ID: US20250144038A1
- Status: Published application
- Kind: A1
- Application number: 18/990,391
- Filed: 2024-12-20
- Published: 2025-05-08
- Earliest claimed: 2021-06-08
- Assignees: University of Georgia Research Foundation, Inc.
- Applicants: University of Georgia Research Foundation, Inc.
- Inventors: Sheba M. J. MohanKumar; Puliyur S. MohanKumar; Yen-Jun Chuang
- Web page: https://patentgrep.com/patent/US20250144038A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Nanoparticles and formulations for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agent can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivate ribosomes of gonadotroph cells and/or prevent or reduce secretion of follicle-stimulating hormones in the subject. Uses for formulations incorporating the nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are also disclosed.

## Claims

### Claim 1

A plurality of nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject, wherein the nanoparticles comprise
a cage,
a surface modifying agent,
a targeting ligand, and
an active agent,
wherein the cage is a zeolitic imidazolate framework (“ZIF”),
wherein the surface modifying agent is attached to an outer surface of the cage and wherein the targeting ligand is exposed to a surrounding environment,
wherein the targeting ligand is a gonadotropin-releasing hormone (“GnRH”) receptor agonist, or a follicle stimulating hormone (“FSH”) receptor agonist, or a luteinizing hormone (“LH”) receptor agonist, or a combination thereof, and
wherein the active agent is encapsulated in the cage.

### Claim 2 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the ZIF comprises a metal ion selected from the group consisting of Zn+, Zn2+, Pd2+, Pd4+, Pt2+, Pt4+, Ni+, Ni2+, Ni3+, Mn2+, Mn3+, Mn4+, Mn6+, Mn7+, Co2+, Co3+, Cu2+, Cd2+, Fe2+, Fe3+, and Ti4+.

### Claim 3 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the ZIF comprises imidazolate functionalized with amine, hydroxyl, thiol, aldehyde, or carboxyl, or a combination thereof.

### Claim 4 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the ZIF is ZIF-2, ZIF-3, ZIF-4, ZIF-8, ZIF-10, ZIF-11, ZIF-12, ZIF-14, ZIF-20, ZIF-21, ZIF-60, ZIF-61, ZIF-62, ZIF-64, ZIF-65, ZIF-66, ZIF-67, ZIF-68, ZIF-69, ZIF-70, ZIF-71, ZIF-72, ZIF-73, ZIF-74, ZIF-75, ZIF-76, ZIF-77, ZIF-78, ZIF-81, ZIF-82, ZIF-90, ZIF-91, ZIF-92, ZIF-95, or ZIF-100.

### Claim 5 (depends on 1)

The plurality of nanoparticles of claim 1, wherein at least 20 wt %, at least 25 wt %, at least 30 wt %, at least 35 wt %, at least 40 wt %, at least 45 wt %, at least 50 wt %, at least 55 wt %, at least 60 wt %, at least 65 wt %, at least 70 wt %, at least 75 wt %, at least 80 wt %, at least 85 wt %, at least 90 wt %, at least 95 wt %, in a range from 20 wt % to 100 wt %, from 30 wt % to 100 wt %, or from 40 wt % to 100 wt % of the surface modifying agent is conjugated to the targeting ligand.

### Claim 6 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the end of the surface modifying agent that is attached to the cage comprises a chemical moiety containing one or more negative charges.

### Claim 7 (depends on 6)

The plurality of nanoparticles of claim 6, wherein the chemical moiety is folate, L-methylfolate, or glutamate, or a combination thereof.

### Claim 8 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the surface modifying agent comprises a polymer backbone selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, poly(lactic-co-glycolic acid), polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(lactide-coaprolactone), and polyethylenimine, and a copolymer thereof.

### Claim 9 (depends on 8)

The plurality of nanoparticles of claim 8, wherein the polymer backbone has a molecular weight in a range from about 1 kDa to about 10 kDa, from about 2 kDa to about 10 kDa, from about 3 kDa to about 10 kDa, from about 4 kDa to about 10 kDa, from about 1 kDa to about 9 kDa, from about 2 kDa to about 9 kDa, from about 3 kDa to about 9 kDa, from about 4 kDa to about 9 kDa, from about 1 kDa to about 8 kDa, from about 2 kDa to about 8 kDa, from about 3 kDa to about 8 kDa, from about 4 kDa to about 8 kDa, from about 1 kDa to about 7 kDa, from about 2 kDa to about 7 kDa, from about 3 kDa to about 7 kDa, from about 4 kDa to about 7 kDa, from about 1 kDa to about 6 kDa, from about 2 kDa to about 6 kDa, from about 3 kDa to about 6 kDa, or from about 4 kDa to about 6 kDa.

### Claim 10 (depends on 1)

The plurality of nanoparticles of claim 1, having an average diameter in a range from about 10 nm to about 100 nm, from about 10 nm to about 90 nm, from about 10 nm to about 80 nm, from about 20 nm to about 100 nm, from about 20 nm to about 90 nm, from about 20 nm to about 80 nm, from about 30 nm to about 100 nm, from about 30 nm to about 90 nm, or from about 30 nm to about 80 nm.

### Claim 11 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the surface density of the surface modifying agent (“SMA”) on the surface of the nanoparticle is at least 1 SMA/nm2, at least 5 SMA/nm2, at least 7 SMA/nm2, at least 10 SMA/nm2, at least 15 SMA/nm2, at least 20 SMA/nm2, at least 25 SMA/nm2, at least 30 SMA/nm2, at least 35 SMA/nm2, at least 40 SMA/nm2, at least 45 SMA/nm2, or at least 50 SMA/nm2.

### Claim 12 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the active agent is a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof.

### Claim 13 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the polymer backbone of the surface modifying agent is polyethylene glycol.

### Claim 14 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the active agent is a ribosome inactivating protein.

### Claim 15 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the active agent is saporin, gelonin, or a pokeweed antiviral protein (“PAP”), or a combination thereof.

### Claim 16 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the targeting ligand is buserelin, azagly-naflorein, deslorelin, fertirelin, gonadorelin, goserelin, histrelin, lecirelin, leuprorelin, nafarelin, peforelin, peforelin acetate, triptorelin, leuprolide, leuprolide acetate, abarelix, cetorelix, degarelix, elagolix, ganirelix, linzagolix, relugolix, thiazolidinone compound 5, hexahydroquinoline derivative Org 214444-0, thienopyrimidine derivatives, such as thienopyrimidine derivative Org 43553, 5-amino-N-(tert-butyl)-4-(3-(isonicotinamido)phenyl)-2-(methylthio)thieno-[2,3-d]pyrimidine-6-carboxamide, 5-amino-N-(tert-butyl)-2-(methylthio)-4-(3-(thiophene-3-carboxamido)phenyl thieno[2,3-d]pyrimidine-6-carboxamide, 5-amino-N-(tert-butyl-2-(methylsulfonyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]pyrimidine-6-carboxamide, 5-amino-N-(tert-butyl-4-(3-(1-methyl-1H-pyrazole-4-carboxamido)phenyl)-2-(methylsulfanyl)thieno[2,3-d]pyrimidine-6-carboxamide, 5-amino-N-(tert-butyl)-4-(3-(2-metoxynicotinamido)phenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide, 4-((3-(5-amino-6-(tert-butylcarbamoyl)-2-(methylthio)thieno[2,3-d]pyrimidine-4-il)phenyl)carbamoyl)pyridine 1-oxide, and 5-amino-N-(tert-butyl)-4-(3-(2-chloronicotinamido)phenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide; a diketopiperazine, or m-dihydropyridine, or a combination thereof.

### Claim 17 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the targeting ligand is buserelin.

### Claim 18 (depends on 1)

The plurality of nanoparticles of claim 1, wherein the nanoparticles further comprise a dye molecule.
